CORDENPHARMA COLORADO (US)
Highly Potent API Video
CordenPharma 15 Year Anniversary
Core Capabilities
- >> Development & manufacturing of advanced intermediates & chemically synthesized APIs
- >> Focus on synthetic peptides, oligonucleotides, highly potent cytotoxic and non-cytotoxic APIs
- >> Large-scale peptide production
- >> Manufacture of high volume small molecule APIs
- >> Green manufacturing (green solvent, recycling concept for upstream & downstream solvent for peptides)
COMPLIANCE
- >> Good inspection history with the FDA, last inspection 2019
- >> No violations on any DEA Inspections
- >> No violations on Colorado Board of Pharmacy inspections
2019 SHE Regulatory Inspections
- >> US EPA Hazardous Waste Leak Detection and Repair Inspection: One finding
- >> State of Colorado Air Permit Inspection (Federal Title V Permit): No findings
- >> State of Colorado Hazardous Waste Inspection: No findings
- >> City of Boulder Industrial Pretreatment Inspection (Waste Water): No findings
- >> Boulder County (Ozone Depleting Substances): No findings
- >> Boulder Fire Department: No findings
Related Products & Platforms
Technology Platforms
Facility Legacy
CordenPharma Colorado is a world leader in the development and manufacturing of chemically synthesized peptide APIs. Starting as a technology-based contract manufacturing business in 1946, it has contributed important technical advances to API manufacturing, most recently in the fields of highly active compounds and peptide synthesis. The facility is registered globally for producing four APIs and several intermediates. In addition, it has supplied clinical trials in a large number of small molecule and peptide projects, and developed second generation processes for high volume small molecules.
As a former facility of Roche, CordenPharma Colorado brings expertise in peptide and small molecule manufacturing which has been realized through significant investments in advanced chemical process equipment and state-of-the-art environmental facilities and infrastructure.
HISTORY
- >> 1946 – 1965: Arapahoe Chemicals founded in Boulder with a focus on producing fine organic chemicals
- >> 1965 – 1994: Acquired by Syntex Corporation, a company founded in Mexico City with a focus on oral contraceptives. Boulder production focused on Naprosyn® and highly active compounds
- >> 1994 – 2011: Acquired by Roche, a global healthcare company based in Basel, Switzerland. Boulder production focused on peptides, highly active compounds and complex small molecules
- >> 2011: Acquired by ICIG to become CordenPharma Colorado
- >> 2022 Astorg acquires CordenPharma from ICIG
Managing Director
Craig Dixon
Corden Pharma Colorado
2075 55th Street
Boulder, Colorado 80301
Phone: +1 (303) 442 1926
Fax: +1 (303) 938 6413